More recently, we reported that pH-sensitive anti-CTLA-4 antibodies are more effective in ADCC and tumor rejection [19], which raise the issue as to whether increasing ADCC activity jeopardizes the selectivity of the antibodies. This evidence concerns the gene CTLA4 and neoplasm.